Autifony Therapeutics
Autifony Therapeutics is a London-based, clinical-stage biopharmaceutical company developing SENS-401, a Kv3 channel modulator drug candidate aimed at treating sensorineural hearing loss and tinnitus in patients with limited pharmacological options.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Autifony Therapeutics does
Autifony Therapeutics is a London-based, clinical-stage biopharmaceutical company founded in 2011 that develops novel small-molecule drug therapies for hearing disorders, principally sensorineural hearing loss and tinnitus. Its lead asset, SENS-401, is a Kv3 potassium channel modulator positioned in the hearing-loss clinical-trial pipeline alongside assets such as ACOU085, OTO-413, and DB-020, addressing a therapeutic area with limited pharmacological options and significant unmet medical need. The company operates in a competitive landscape of more than 30 companies pursuing over 35 pipeline drugs for hearing-related conditions.
The company is privately held, employs between 11 and 50 people, and is led by founder and CEO Charles Large. To date, Autifony has disclosed approximately US$39.7m in cumulative funding across five rounds (2011, 2013, 2014, 2015, and a 2017 Innovate UK grant), with investors including Imperial Innovations, SV Health Investors, Pfizer Venture Investments, International Biotechnology Trust, UCLB, and Innovate UK. The most recent disclosed capital event is a March 2017 Innovate UK grant of approximately US$1.6m, and no commercial revenue, pricing, partnerships, or post-2017 milestones are visible in the source data. As a pre-commercial drug developer, Autifony's business model is contingent on advancing SENS-401 (and potentially related Kv3 modulators) through clinical development, with future monetization expected to come from out-licensing, partnership, or eventual commercialization rather than direct product sales.
Autifony Therapeutics firmographics
Firmographics- Name
- Autifony Therapeutics
- Website
- https://autifony.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Short description
- Autifony Therapeutics is a London-based, clinical-stage biopharmaceutical company developing SENS-401, a Kv3 channel modulator drug candidate aimed at treating sensorineural hearing loss and tinnitus in patients with limited pharmacological options.
- Ownership category
- akta.pro rank
Autifony Therapeutics industry classification
Industry- Product category
- Otology Pharmaceuticals (Hearing Loss Therapeutics)
- NAICS
- Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industry
- Ophthalmic & Otic Generics (HLAIABAF)
Keywords
Where Autifony Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Autifony Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Autifony Therapeutics product offering
Product offeringCore offering
Autifony Therapeutics is a clinical-stage biopharmaceutical company that develops novel small-molecule drug therapies for hearing disorders, principally hearing loss and tinnitus. Its lead asset, SENS-401, is being advanced through clinical development as a pharmacological treatment for hearing loss, an indication with limited existing drug options. The company is one of 30+ organizations working on 35+ pipeline drugs in the hearing loss therapeutic area.
Product overview
Autifony Therapeutics is a pharmaceutical company focused on developing drug therapies for hearing loss and related conditions. Based on the source data, the company is identified as one of 30+ companies contributing to the hearing loss clinical trial development pipeline with multiple pipeline drugs under investigation. However, no specific branded products, named drug candidates, or detailed product/service descriptions are provided in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- SENS-401
Companies that use Autifony Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Autifony Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Autifony Therapeutics partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Autifony Therapeutics competitors and assessment
Company assessmentDirect peers
- Otonomy: Clinical-stage biopharmaceutical company developing therapeutics for otology indications including hearing loss and balance disorders; directly comparable as a small public US biotech pursuing pharmacological treatments for the same patient population as Autifony's SENS-401.
- Decibel Therapeutics: Clinical-stage biotech developing therapeutics to protect, repair and restore hearing; an extremely close peer because it pursued small-molecule and gene-therapy approaches to hearing loss — the same focus area as Autifony — and was ultimately acquired by Eli Lilly in 2023.
- Frequency Therapeutics: Clinical-stage regenerative medicine biotech developing drug candidates to restore hearing function; directly comparable as another sponsor in the hearing-loss pharmacology pipeline that competed against SENS-401 for partnership and capital attention.
- Pipeline Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for hearing loss; an especially close peer because it pursued a small-molecule, ion-channel-adjacent mechanism, matching Autifony's pharmacology-led approach in the same indication.
- Akouos: Clinical-stage gene therapy company focused on hearing loss; directly comparable as another hearing-loss focused biotech that ultimately transacted with a large pharma (acquired by Lilly), establishing a recent comparable-exit precedent for Autifony.
- Sensorion: European clinical-stage biotech developing novel therapies for hearing-loss disorders including sudden sensorineural hearing loss and vertigo; highly comparable given its European base, similar clinical-stage profile and overlapping otology pipeline.
Emerging players
- Sound Pharmaceuticals: Clinical-stage biotech developing therapeutics for hearing loss and ototoxicity; comparable as a smaller, hearing-loss-only focused biopharma working on pharmacological treatments for similar otology indications as Autifony.
Broad incumbents
- Eli Lilly: Large pharmaceutical company that acquired both Decibel Therapeutics and Akouos in 2023 to anchor a hearing-loss franchise; comparable as the most active strategic acquirer in Autifony's space and a potential partner or acquirer for SENS-401.
- Cochlear Limited: Global leader in implantable hearing devices; broadly comparable as the dominant commercial player in the hearing-loss treatment landscape that Autifony would either partner with or compete against if SENS-401 reaches the market.
Regional players
- Kyorin Pharmaceutical: Japan-focused specialty pharmaceutical company with a legacy franchise in otic/ENT therapeutics; comparable as a regional player with active otic pharmaceutical development outside Autifony's primary UK/EU and US target markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Autifony Therapeutics social profiles
Digital presenceAutifony Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Autifony Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Autifony Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Autifony Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Autifony Therapeutics
What does Autifony Therapeutics do?
Autifony Therapeutics is a clinical-stage biopharmaceutical company that develops novel small-molecule drug therapies for hearing disorders, principally hearing loss and tinnitus. Its lead asset, SENS-401, is being advanced through clinical development as a pharmacological treatment for hearing loss, an indication with limited existing drug options. The company is one of 30+ organizations working on 35+ pipeline drugs in the hearing loss therapeutic area.
When was Autifony Therapeutics founded?
Autifony Therapeutics was founded in 2011. It employs 11 to 50 people.
Where is Autifony Therapeutics based?
Autifony Therapeutics is headquartered in London, United Kingdom, in the Europe region.
Who are Autifony Therapeutics's main competitors?
Direct peers on record are Otonomy, Decibel Therapeutics, Frequency Therapeutics, Pipeline Therapeutics, Akouos and Sensorion. Sound Pharmaceuticals is listed as an emerging player. Broad incumbents are Eli Lilly and Cochlear Limited. Kyorin Pharmaceutical is listed as a regional player.
Does Autifony Therapeutics have an API?
No public API is recorded for Autifony Therapeutics.
What industry is Autifony Therapeutics in?
Autifony Therapeutics's product category is Otology Pharmaceuticals (Hearing Loss Therapeutics). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAIABAF, Ophthalmic & Otic Generics. Its NAICS code is 5417 and its SIC code is 2834.